Therapeutic benefit of idebenone in patients with Leber hereditary optic neuropathy: The LEROS nonrandomized controlled trial.

Patrick Yu-Wai-Man, Livia Tomasso, Neringa Jurkutė, Magdalena Korwin, Audrey Meunier, Sylvia Cherninkova, Ali Yagan, Francisco Jose Muñoz-Negrete, Marc H Levin, Steven Newman, Prem S Subramanian, Wojciech Lubiński, Gregory Van Stavern, Aki Linden, Magda Joana Silva, Thomas Klopstock, Jacek Dziedziak, Marta Misiuk-Hojło, Valerio Carelli, Marcela Votruba, Chiara La Morgia, Jacek P Szaflik, Berthold Pemp, David Katz, Jarosław Kocięcki, Nancy J Newman, Xavier Llòria, Lorena Castillo, Rudrani Banik, Claudia Priglinger, Joshua P Harvey, Yaping Joyce Liao

Journal: Cell reports. Medicine 2024;5(3):101437

PMID: 38428428

Abstract

Leber hereditary optic neuropathy (LHON) is a mitochondrial disease leading to rapid and severe bilateral vision loss. Idebenone has been shown to be effective in stabilizing and restoring vision in patients treated within 1 year of onset of vision loss. The open-label, international, multicenter, natural history-controlled LEROS study (ClinicalTrials.gov NCT02774005) assesses the efficacy and safety of idebenone treatment (900 mg/day) in patients with LHON up to 5 years after symptom onset (N = 199) and over a treatment period of 24 months, compared to an external natural history control cohort (N = 372), matched by time since symptom onset. LEROS meets its primary endpoint and confirms the long-term efficacy of idebenone in the subacute/dynamic and chronic phases; the treatment effect varies depending on disease phase and the causative mtDNA mutation. The findings of the LEROS study will help guide the clinical management of patients with LHON.

Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.

Address: John van Geest Centre for Brain Repair, University of Cambridge, Cambridge CB2 0PY, UK; MRC Mitochondrial Biology Unit, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0XY, UK; Cambridge Eye Unit, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK; Moorfields Eye Hospital NHS Foundation Trust, London EC1V 2PD, UK; Institute of Ophthalmology, University College London, London EC1V 9EL, UK.; IRCCS Istituto di Scienze Neurologiche di Bologna, Programma di Neurogenetica, 40139 Bologna, Italy; Department of Biomedical and Neuromotor Sciences, University of Bologna, 40127 Bologna, Italy.; Departments of Ophthalmology, Neurology, and Neurological Surgery, Emory University School of Medicine, Atlanta, GA 30322, USA.; All is Data, 4052 Basel, Switzerland.; EstiMates Oy, 20520 Turku, Finland.; Washington University in St. Louis, St. Louis, MO 63130, USA.; Department of Ophthalmology, Medical University of Warsaw, 02-091 Warsaw, Poland; SPKSO Ophthalmic University Hospital, 00-576 Warsaw, Poland.; New York Eye and Ear Infirmary of Mount Sinai, New York, NY 10003, USA.; Samodzielny Publiczny Szpital Kliniczny Nr 2 PUM w Szczecinie, 70-111 Szczecin, Poland.; Department of Ophthalmology, Medical University of Vienna, 1090 Vienna, Austria.; Stanford University Byers Eye Institute, Palo Alto, CA 94303, USA.; Sue Anschutz-Rodgers University of Colorado Eye Center, Aurora, CO 80045, USA.; Wrocław Medical University, 50-556 Wrocław, Poland.; University of Virginia, Charlottesville, VA 22903, USA.; Institut Catala de Retina (ICR), 08022 Barcelona, Spain.; Department of Ophthalmology, University of Medical Sciences, 60-806 Poznan, Poland.; Department of Ophthalmology, Palo Alto Medical Foundation, Palo Alto, CA 94303, USA.; Hospital Universitario Ramon y Cajal, IRYCIS, Universidad Alcalá, 28034 Madrid, Spain.; Manchester Royal Eye Hospital, Manchester M13 9WL, UK.; UMHAT "Alexandrovska" EAD, 1431 Sofia, Bulgaria.; Bethesda Neurology LLC, Bethesda, MD 20852, USA.; Department of Ophthalmology, CHU Saint-Pierre, 1000 Brussels, Belgium.; Cardiff Eye Unit, University Hospital of Wales, Cardiff CF14 4XW, UK.; Department of Ophthalmology, Medical University of Warsaw, 02-091 Warsaw, Poland; SPKSO Ophthalmic University Hospital, 00-576 Warsaw, Poland; Department of Experimental and Clinical Physiology, Center for Preclinical Research, Medical University of Warsaw, 02-097 Warsaw, Poland.; Moorfields Eye Hospital NHS Foundation Trust, London EC1V 2PD, UK; Institute of Ophthalmology, University College London, London EC1V 9EL, UK; The National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London WC1N 3BG, UK.; Moorfields Eye Hospital NHS Foundation Trust, London EC1V 2PD, UK; Institute of Ophthalmology, University College London, London EC1V 9EL, UK.; IRCCS Istituto di Scienze Neurologiche di Bologna, Programma di Neurogenetica, 40139 Bologna, Italy; Department of Biomedical and Neuromotor Sciences, University of Bologna, 40127 Bologna, Italy; IRCCS Istituto delle Scienze Neurologiche di Bologna, 40139 Bologna, Italy.; Department of Ophthalmology, University Hospital of the Ludwig-Maximilians-University (LMU), 80336 Munich, Germany.; Chiesi Farmaceutici S.p.A., 43100 Parma, Italy.; German Center for Neurodegenerative Diseases (DZNE), 81377 Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany; Friedrich Baur Institute at the Department of Neurology, LMU University Hospital, LMU Munich, 80336 Munich, Germany. Electronic address: [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.